Abeona Therapeutics (ABEO) Stock Price, Quote & News

Latest News on ABEO

Dec 31, 2024, 7:30 AM EST - 17 days ago

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 14, 2024, 7:30 AM EST - 2 months ago

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 12, 2024, 7:30 AM EST - 2 months ago

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Nov 4, 2024, 7:30 AM EST - 2 months ago

Abeona Therapeutics® Announces Participation in November Investor Conferences

Oct 29, 2024, 7:30 AM EDT - 2 months ago

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Oct 3, 2024, 8:09 AM EDT - 3 months ago

Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy

Sep 3, 2024, 7:30 AM EDT - 4 months ago

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Aug 14, 2024, 7:30 AM EDT - 5 months ago

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Aug 13, 2024, 7:30 AM EDT - 5 months ago

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Aug 12, 2024, 7:30 AM EDT - 5 months ago

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Jul 12, 2024, 4:59 PM EDT - 6 months ago

Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones

Jul 11, 2024, 7:30 AM EDT - 6 months ago

Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications

Jul 8, 2024, 7:30 AM EDT - 6 months ago

Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum

Jun 3, 2024, 7:30 AM EDT - 8 months ago

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 28, 2024, 7:30 AM EDT - 8 months ago

Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference

May 15, 2024, 7:30 AM EDT - 8 months ago

Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress

May 3, 2024, 7:30 AM EDT - 9 months ago

Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

May 2, 2024, 5:50 PM EDT - 9 months ago

Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL

May 2, 2024, 11:00 AM EDT - 9 months ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

Apr 29, 2024, 7:11 PM EDT - 9 months ago

The Law Offices of Frank R. Cruz Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

Apr 23, 2024, 5:20 PM EDT - 9 months ago

Abeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not Lost

Apr 22, 2024, 4:31 PM EDT - 9 months ago

US FDA declines to approve Abeona's skin disorder treatment

Apr 22, 2024, 4:05 PM EDT - 9 months ago

Abeona Therapeutics Provides Regulatory Update on Pz-cel

Mar 18, 2024, 7:30 AM EDT - 10 months ago

Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections

Feb 1, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)

Jan 8, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics Announces $50 Million Credit Facility

Nov 27, 2023, 7:30 AM EST - 1 year ago

Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

Nov 16, 2023, 4:26 PM EST - 1 year ago

Abeona Therapeutics Inc. (ABEO) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:30 AM EST - 1 year ago

Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments

Sep 26, 2023, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa

Sep 12, 2023, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer

Sep 7, 2023, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Announces Participation in Upcoming Investor Conferences

Aug 30, 2023, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission

Aug 12, 2023, 1:42 PM EDT - 1 year ago

Abeona Therapeutics Inc. (ABEO) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Reports Second Quarter 2023 Financial Results

Jul 28, 2023, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023

Jul 19, 2023, 8:30 AM EDT - 1 year ago

Abeona Therapeutics Joins Rare Disease Company Coalition

Jul 7, 2023, 8:30 AM EDT - 1 year ago

Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 3, 2023, 8:45 AM EDT - 1 year ago

Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 9, 2023, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101

Jun 1, 2023, 7:30 AM EDT - 1 year ago

Abeona Therapeutics to Present at the Jefferies Healthcare Conference

May 24, 2023, 2:54 PM EDT - 1 year ago

Abeona Therapeutics Inc. (ABEO) Q1 2023 Earnings Call Transcript

May 22, 2023, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023

May 16, 2023, 9:00 AM EDT - 1 year ago

Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

May 11, 2023, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Reports First Quarter 2023 Financial Results

May 11, 2023, 7:00 AM EDT - 1 year ago

Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting

Apr 26, 2023, 5:34 AM EDT - 1 year ago

Market Cap	227.79M
Revenue (ttm)	3.50M
Net Income (ttm)	-54.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,548.29%
Debt to Equity Ratio	0.41

Volume	170,200
Avg Vol	271,376
Day's Range	N/A - N/A
Shares Out	43.47M
Stochastic %K	16%
Beta	1.46
Analysts	Strong Sell
Price Target	$15.90